Jeffrey Weitzel, MD
There are many unanswered questions about oncogenes. The practical understanding of these is limited to a handful of genes such as BRCA1/2
. However, broad genetic assays typically yield an amount of data that dwarfs the actionable oncogene subset, based on concrete medical and scientific knowledge. It might be tempting, therefore, to skip the sort of germline DNA test that maps more than a dozen such genes—tempting but, according to leading experts in the field, unwise. Although much remains unknown about many mutations and test results rarely clarify the need for any particular response, panel testing has already demonstrated its cost value, which continues to increase every day. Each new paper has the potential to transform today’s obscure results into tomorrow’s actionable intelligence.
... to read the full story